Onychomycosis (Tinea unguium), a persistent and challenging fungal infection of the nails, poses significant clinical difficulties due to its recurrent nature and resistance to conventional treatments. This review comprehensively analyzes the pathogenesis, therapeutic strategies, and emerging trends in managing this condition. Onychomycosis is primarily caused by various fungal pathogens, most notably dermatophytes such as Trichophyton mentagrophytes and Trichophyton rubrum, accounting for about 60–70% of the cases. Other causative organisms include Candida species and non-dermatophytic molds. Several risk factors predispose individuals to infection, including trauma, diabetes, and immunosuppression, which increase susceptibility to the disease. Due to the complexity of its etiology and the resistance profile of the fungi involved, effective management requires a multifaceted approach, incorporating systemic and topical antifungal agents and emerging therapies such as laser treatment and photodynamic therapy. Furthermore, rising trends in molecular diagnostic techniques and novel antifungal formulations offer promising advancements in combating this resilient infection. The pathogenesis involves fungal irruption of the nail plate and posterior vulnerable response, causing characteristic clinical instantiations observed in cases. This disease manifestation can be divided into distal and proximal subungual types, superficial white and total dystrophic donations, each with distinct clinical features and individual challenges. Opinion relies on clinical assessment and laboratory tests, frequently taking fungal culture or microscopy for evidence. Treatment options encompass topical ointments similar to a five result of Tavaborole (the first antifungal agent that is used topically) and systemic antifungal medicines similar to terbinafine, amorolfine, efinaconazole with combination remedy (using CO2 as ray and topical remedy) and surgical interventions reserved for severe cases. Still, challenges similar to antifungal resistance and case adherence persist, challenging new remedial approaches and forestallment strategies. Arising trends in onychomycosis operation focus on combating resistance, enhancing individual delicacy, and exploring indispensable treatments. Advancements in molecular diagnostics and targeted curatives offer promising avenues for individualized treatment rules. Also, preventative measures, including patient education and better hygiene practices, are pivotal in reducing the complaint burden.